StemEdit iMSC B2M/CIITA DKO ReproMSC14

Hypoimmune Human iPSC-derived MSCs with B2M and CIITA Double Knockout 

Repro MSC14 are ready-to-use iPSC-derived mesenchymal stem cells (iMSCs) generated from StemEdit hiPSC B2M/CIITA DKO (Cat. No. RCRP052), a gene-edited version of one of our StemRNA™ Clinical Lines, RPC-LLF-34-F3.  The analogous wild-type iMSCs line (Repro MSC10 iPSC-derived MSCs (iMSCs), Phenol Red-Free, Cat. No. RCRP038) is also available.

ReproMSC14 cells do not contain Phenol Red, making them ideal for exosome research.

iPSC-derived MSCs, sometimes called iMSCs, offer several advantages over primary MSCs, including a renewable cell source, enhanced scalability, greater batch-to-batch consistency, high proliferative capacity, and suitability for genetic engineering. Find out more about their potential therapeutic advantages in our recent blog post "The Therapeutic Advantage of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells (iMSCs)".

ReproMSC14 cells feature:

• Easy access to hypoimmune MSCs from a reproducible source.
• Immediate thawing into Phenol Red-free MSC NutriStem XF Culture medium (Cat. No. 01-0007) on vitronectin or NutriCoat™ Attachment Solution (Cat. No. 05-0063) with easy conversion to other standard MSC Media.

NOTE:  

These iMSC cell lines are developed and supplied for Research Use Only (RUO). They are not intended for clinical or therapeutic applications. However, the iPSC clone from which these iMSCs were derived has a clinical-grade iPSC counterpart that is suitable for clinical gene editing and downstream clinical development. If you require material for translational or clinical programs, please see Clinical Stem Cell Services or Contact Us for more information.

See also our complete collections of Research Use Only ReproMSC iPSC-derived MSCs (iMSCs) and StemEdit Gene-Edited iPSC Lines.